Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: A retrospective study

Haematologica

Volumn 86, Issue 7, 2001, Pages 749-752

  Narvios, A B ^a   Lichtiger, B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone marrow transplantation; CMV prevention; Leukoreduction; Transfusion

Indexed keywords

IMMUNOGLOBULIN;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD COMPONENT THERAPY; BLOOD DONOR; BLOOD FILTRATION; CHILD; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; LEUKOCYTE; MALE; SEROLOGY; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; BONE MARROW TRANSPLANTATION; CHILD; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; POINT-OF-CARE SYSTEMS; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034912335     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Methods for the reduction of transfusion-transmitted cytomegalovirus infection: Filtration versus the use of seronegative donor units
2. Role of leukocyte depletion in the prevention of transfusion-induced cytomegalovirus infection
3. Risk factors for cytomegalovirus infection after human marrow transplantation
4. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: Where do we stand?
5. Prevention of transfusion acquired cytomegalovirus infection in infants by blood filtration to remove leukocytes
6. The role of blood product filtration in the prevention of cytomegalovirus (CMV) infection after bone marrow transplant
7. Leukocyte reduction for the prevention of transfusion-transmitted cytomegalovirus (TT-CMV)
8. Bedside platelet leukoreduction is as effective as that performed in the blood bank
9. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients
10. Canadian Red Cross Society symposium on leukodepletion: Report of proceedings
11. Leukocyte reduction of cellular blood components. Effectiveness, benefits, quality control, and costs
12. The role of leukodepletion in the control of transfusion-transmitted disease
13. Laboratory serologic problems associated with administration of intravenous IgG